First Time Loading...

BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 1.86 USD Market Closed
Updated: May 29, 2024

BioXcel Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioXcel Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
BioXcel Therapeutics Inc
NASDAQ:BTAI
Cash Equivalents
$74.1m
CAGR 3-Years
-27%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$18.1B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$4.7B
CAGR 3-Years
5%
CAGR 5-Years
-23%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.7B
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
26%
CAGR 10-Years
36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.6B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
19%

See Also

What is BioXcel Therapeutics Inc's Cash Equivalents?
Cash Equivalents
74.1m USD

Based on the financial report for Mar 31, 2024, BioXcel Therapeutics Inc's Cash Equivalents amounts to 74.1m USD.

What is BioXcel Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
15%

Over the last year, the Cash Equivalents growth was -55%. The average annual Cash Equivalents growth rates for BioXcel Therapeutics Inc have been -27% over the past three years , 15% over the past five years .